Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple MRI replace a PET scan for safer cancer radiation?

NCT ID NCT07609225

Not yet recruiting Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study will test whether a special MRI scan (CSE-MRI) can accurately measure active bone marrow in men with metastatic prostate cancer, compared to a standard PET scan using a radioactive tracer (FLT). Fifteen participants will receive both scans at the same time using a combined PET/MRI machine. If the MRI works as well as the PET scan, it could help doctors better protect bone marrow during radiation therapy, reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-FLT (fluorothymidine) injection
What this could lead to
If successful, this could show that a simpler MRI scan can replace a PET scan for measuring active bone marrow, potentially making radiation therapy safer and more accessible.
What could go wrong
This is a very small, early-phase study with only 15 participants. It is testing imaging accuracy, not a treatment, so it will not directly improve health outcomes. The MRI method may not prove as reliable as PET.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.